Back to search results

Symptom Monitoring in Hemodialysis (SMaRRT-HD) Trial

This study, called SMaRRT-HD, is looking at whether regularly tracking symptoms and having clinicians follow up can improve care for people with end-stage kidney disease who are on hemodialysis. You might be able to join if you are 18 or older, receive hemodialysis at a participating clinic, and speak English or Spanish. The study is comparing two approaches: one group of clinics will use the SMaRRT-HD system to collect your symptoms and help your care team respond, while the other group will continue with usual care. The main goal is to see if using SMaRRT-HD reduces how severe your dialysis-related symptoms are over 12 months. This study is currently recruiting about 2400 patients across the US.

Study design
This is an interventional study that will enroll approximately 2400 participants. It is a cluster randomized trial, meaning groups of dialysis clinics will be assigned to either use the SMaRRT-HD system or continue with usual care.
What's involved
If your clinic is assigned to the SMaRRT-HD group, you would report your symptoms using the SMaRRT-HD platform. Clinics in the SMaRRT-HD group will adopt its use for 12 months.
Compensation
Not stated in the trial record.
Follow-up
Your symptom severity will be measured at the start of the study, at 6 months, and at 12 months.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT05738330

Symptom Monitoring in Hemodialysis

Recruiting
NAAges 18+InterventionalSupportive care
University of Pennsylvania
~2,400 participants
Updated 2025-11-24 on ClinicalTrials.gov
What's tested:Symptom Monitoring on Renal Replacement Therapy - Hemodialysis (SMaRRT-HD)Usual Care

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Severity of dialysis-associated symptoms (Effectiveness)
Measured over Baseline, 6 months, 12 months

Conditions

End Stage Kidney Disease

Explore related trials

Chronic Kidney Disease, Stage 5

Where it's being run

1 sites across 1 states
Massachusetts1

Study leadership

  • Jennifer Flythe, MD · PRINCIPAL_INVESTIGATOR · University of North Carolina, Chapel Hill
  • Laura Dember, MD · PRINCIPAL_INVESTIGATOR · University of Pennsylvania

Who to contact

Cassandra Bowman, MHA
[email protected]
919-445-6790
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Age ≥ 18 years
Treatment with hemodialysis at a participating dialysis clinic
English or Spanish speaking

Exclusion

Not willing to report their symptoms using the SMaRRT-HD platform
Not willing to share clinically acquired data with the research team
Underlying condition such as dementia that is anticipated to prevent comprehension of the trial information document (fact sheet)
Incarceration

What this trial measures

  • Severity of dialysis-associated symptoms (Effectiveness)Baseline, 6 months, 12 months

    This outcome will be assessed as change in the Dialysis Symptom Index-Severity Score over 12 months (primary endpoint). Participants are asked whether or not they experienced symptoms during the past week. If the response is yes, the participant is asked to indicate "How much did it bother you?". Lowest score - 0; Highest score - 150. A higher score indicates a worse outcome.